• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

    4/11/25 4:05:00 PM ET
    $NXPL
    $OPK
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXPL alert in real time by email

    The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities for Future US-Produced Products Including its Florida Sunshine Brand of Vitamins and Supplements Due to Tariff Impact

    COCONUT GROVE, Fla., April 11, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global e-Commerce provider, today provided an update on the impact of current United States/China tariffs on its e-Commerce development program as a result of China's escalation in tariffs placed on US-produced goods imported into the country. This condition is expected to have a material impact on anticipated sales of US products into China.

    NextPlat Corp. logo (PRNewsfoto/NextPlat Corp.)

    The Company plans to pause certain initiatives within its e-Commerce development program which was launched in April 2023 to help U.S.-based businesses reach the vast Chinese consumer market through major online platforms like Alibaba's Tmall. This includes the introduction of a new line of vitamins and supplements under the Florida Sunshine brand name, since these offerings would be subject to the increased tariffs and would face significant import costs which Management believes will reduce its ability to compete with locally produced products. The Company is still reviewing opportunities to sell its Florida Sunshine products in other markets.

    The Company intends to continue selling OPKO Health Europe (OPKO), a subsidiary of OPKO Health, Inc. (NASDAQ:OPK), products in China including an array of nutraceuticals and supplements as well as adding products for pet care, all of which are not produced in the United States and as such, are not subject to additional tariffs.

    For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X.

    About NextPlat Corp

    NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the Company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care LLC.

    Forward-Looking Statements

    Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services, or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to introduce new products and services and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

    Media and Investor Contact for NextPlat Corp:

    Michael Glickman

    MWGCO, Inc.

    917-397-2272

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-provides-statement-on-us-tariff-impact-on-its-e-commerce-development-program-302426823.html

    SOURCE NextPlat Corp.

    Get the next $NXPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXPL
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $NXPL
    $OPK
    SEC Filings

    View All

    SEC Form S-8 filed by NextPlat Corp

    S-8 - NextPlat Corp (0001058307) (Filer)

    1/30/26 4:49:02 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Amendment: NextPlat Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - NextPlat Corp (0001058307) (Filer)

    1/13/26 9:05:50 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    SEC Form EFFECT filed by NextPlat Corp

    EFFECT - NextPlat Corp (0001058307) (Filer)

    1/9/26 12:15:12 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barreto Rodney was granted 21,176 shares, increasing direct ownership by 5% to 445,585 units (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:32:15 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Director Armas Anthony was granted 10,588 shares (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:28:57 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Director Ellenoff Douglas was granted 21,176 shares, increasing direct ownership by 15% to 166,176 units (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:24:49 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

    This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industry veteran Steve Rubin joins Entera's board MIAMI and TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO

    2/4/26 8:00:00 AM ET
    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website here. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large,

    1/6/26 4:11:42 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextPlat Expects Significant Sequential Quarterly Growth in 340B Revenue in the Fourth Quarter of 2025 as it Further Expands its Business Development Efforts

    New Business Initiatives Implemented in the Second Half of 2025 Contributing to Nearly 75% Sequential Quarterly Revenue Growth in 340B Contract Revenue HALLANDALE BEACH, Fla., Dec. 10, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced continued progress in its business development efforts as it executes against its growth and organizational refocusing initiatives. The Company

    12/10/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    4/25/25 8:32:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Financials

    Live finance-specific insights

    View All

    NextPlat Reports Third Quarter 2025 Results

    Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026  HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the quarter-ended September 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

    11/13/25 8:03:00 AM ET
    $BABA
    $NXPL
    $OPK
    Real Estate
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations

    NextPlat to Release Third Quarter 2025 Results on Thursday, November 13, 2025

    Investor Conference Call Scheduled for Thursday, November 13, 2025 at 8:30 a.m. Eastern HALLANDALE BEACH, Fla., Nov. 3, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the quarter ended September 30, 2025 before market open on November 13, 2025. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial

    11/3/25 8:03:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

    MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several indications. ModeX is entitled to receive an upfront payment and potential milestone payments exceeding $200 million for e

    10/29/25 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    NextPlat Appoints Rodney Barreto as Chairman of the Board and David Phipps as Chief Executive Officer to Lead Ongoing Business Refocusing Efforts

    Company Executes on Initiatives Including New Business Development, Corporate Reinvestment and Implements Additional Cost-Cutting Initiatives HALLANDALE BEACH, Fla., Sept. 9, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide, today announced that as part of the Company's ongoing business refocusing plans, it has named Rodney Barreto as its permanent Chairman of the Board and David Phipps as its permanent Chief Executive Officer. Messrs. Barreto and Phipps were both serving in interim roles following the pas

    9/9/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat Accelerates Healthcare Growth with New Leadership and Expanded Sales, Marketing, and Technology Investments

    Veteran Healthcare Leadership to Drive Business Process Improvement, Enhanced Customer Service and Support the Introduction of New Services for 340B and Long-term Care Providers COCONUT GROVE, Fla., Aug. 26, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the strategic expansion of its healthcare operations. This expansion includes a series of developments highlighted by the appointment of new senior leadership and investment into its healthcare operations designed to support its growth in

    8/26/25 8:02:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care